Innate Pharma S.A.

NasdaqGS:IPHA Stock Report

Market Cap: US$149.9m

Innate Pharma Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Jonathan Dickinson

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenure2.9yrs
Board average tenure6.2yrs

Recent management updates

Recent updates

Innate Pharma: Looking Like A Company We'll Regret Ignoring

Nov 25

Innate Pharma: Worth A Deeper Look

Jan 11

Innate Pharma GAAP EPS of €0.08, revenue of €45.59M

Sep 15

Innate stock rises as Sanofi progress on 2nd cancer drug compound, pay €3M

Jul 21

Innate Pharma: Leading The NK Cell Immunotherapy Space

Oct 06

Innate Pharma: Attractive Price, But Comes With Uncertainty

Jan 29

Innate Pharma files $200M equity shelf

Jan 13

Innate Pharma gives back US, EU Lumoxiti rights to AZN

Dec 11

Innate Pharma reports 9M results

Nov 17

EMA grants PRIME tag to Innate Pharma's lacutamab for T-cell lymphoma

Nov 13

CEO

Jonathan Dickinson (56 yo)

less than a year

Tenure

Mr. Jonathan E. Dickinson served as Executive Vice President and General Manager of Europe at Incyte Corp. since June 2019 until October 2024. He served as General Manager of Europe/International and Senio...

Leadership Team

NamePositionTenureCompensationOwnership
Yannis Morel
Executive VP9.7yrs€599.92k0.24%
$ 359.7k
Jonathan Dickinson
Chairman of the Executive Board & CEOless than a yearno datano data
François Romagné
Founderno datano datano data
Eric Vivier
Founder7yrsno data0.26%
$ 389.4k
Marc Bonneville
Founderno datano datano data
Jean Fournié
Founderno datano datano data
Alessandro Moretta
Founderno datano datano data
Frederic Lombard
Senior VP & CFO3.8yrsno data0.014%
$ 21.1k
Sonia Quaratino
Executive VPless than a yearno datano data
Arvind Sood
Executive VPless than a yearno datano data
Henry Wheeler
Vice President of Investor Relations & Communication2yrsno data0.0039%
$ 5.9k
Odile Belzunce
Vice President of Compliance & Operations6yrsno data0.077%
$ 115.3k

2.9yrs

Average Tenure

56yo

Average Age

Experienced Management: IPHA's management team is considered experienced (2.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Mario Sznol
Strategic Advisory Board Member6.2yrsno datano data
Olivier Martinez
Member of Supervisory Boardno datano datano data
Diane Mathis
Strategic Advisory Boardless than a yearno datano data
Gilles Brisson
Independent Member of Supervisory Board17.6yrs€29.00k0.090%
$ 135.3k
Sally Bennett
Independent Supervisory Board Member2.7yrs€45.00k0.0031%
$ 4.6k
Jean-Yves Blay
Independent Member of Supervisory Board7.1yrs€29.00k0.000060%
$ 90.0
Irina Staatz-Granzer
Independent Chairwoman of Supervisory Board15.6yrs€42.00k0.031%
$ 46.5k
Pascale Boissel
Independent Vice Chairperson of the Supervisory Board4.7yrs€60.00k0.0012%
$ 1.9k
Miriam Merad
Chairman of Strategic Advisory Board6.2yrsno datano data
Veronique Chabernaud
Independent Member of Supervisory Board9.8yrs€48.00k0.00082%
$ 1.2k
Katy Rezvani
Strategic Advisory Boardless than a yearno datano data
Aurelien Marabelle
Strategic Advisory Board Member6.2yrsno datano data

6.2yrs

Average Tenure

62.5yo

Average Age

Experienced Board: IPHA's board of directors are considered experienced (6.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 04:03
End of Day Share Price 2025/01/10 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Innate Pharma S.A. is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Olga SmolentsevaBryan Garnier & Co
Yigal NochomovitzCitigroup Inc
Michael Thomas CooperEdison Investment Research